Nkarta Inc. Common Stock (NKTX)
Stock · NASDAQ · Health Care
$1.81as of 10/16/2026
Price chart
Active signals
NKTX Signal Track Record
How signals performed across all stocks →What NKTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 36 | -6.0% | 36% | September 23, 2026 |
| Bollinger Band Breakout | 23 | -10.5% | 26% | September 8, 2026 |
| Bollinger Band Breakdown | 14 | -18.9% | 36% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +5.4% | 62% | October 5, 2026 |
| Any 20-session window (baseline) | -4.1% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutro…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 106
- Website
- www.nkartatx.com/
Fundamentals
- 1-day range
- $1.78$1.94
- Market cap
- $163.84M
- P/E (trailing)
- —
- P/E (forward)
- -1.03
- EPS (trailing)
- $-1.58
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 641.3K
Forecasts
6 analyst ratings
Nkarta Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NKTXNkarta Inc. Common Stock$1.8▼ 6.74%Market cap $163.84MP/E —$1.7$3.72
- INDPIndaptus Therapeutics Inc. Common Stock$2.63▼ 7.72%Market cap $166.55MP/E —$0.92$5.96
- PEPGPepGen Inc. Common Stock$2.6▲ 2.77%Market cap $166.70MP/E —$1.31$7.8
- AARDAardvark Therapeutics Inc. Common Stock$3.78▼ 2.07%Market cap $159.75MP/E —$3.35$16.6
- OKUROnKure Therapeutics Inc. Class A Common Stock$2.1▼ 1.41%Market cap $168.06MP/E —$2.13$5.38
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$10.34▼ 8.25%Market cap $172.81MP/E —$5.5$24.17
- MENSJyong Biotech Ltd. Ordinary Shares$1.84▼ 7.07%Market cap $153.58MP/E —$1.43$63
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NKTX Nkarta Inc. Common Stock | $163.84M | — | $1.8 | ▼ 6.74% | $1.7$3.72 |
| INDP Indaptus Therapeutics Inc. Common Stock | $166.55M | — | $2.63 | ▼ 7.72% | $0.92$5.96 |
| PEPG PepGen Inc. Common Stock | $166.70M | — | $2.6 | ▲ 2.77% | $1.31$7.8 |
| AARD Aardvark Therapeutics Inc. Common Stock | $159.75M | — | $3.78 | ▼ 2.07% | $3.35$16.6 |
| OKUR OnKure Therapeutics Inc. Class A Common Stock | $168.06M | — | $2.1 | ▼ 1.41% | $2.13$5.38 |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $172.81M | — | $10.34 | ▼ 8.25% | $5.5$24.17 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $153.58M | — | $1.84 | ▼ 7.07% | $1.43$63 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Paul J. Hastings · June 18, 2026 · Sale1.8K @ $2.71
- Vratsanos George · June 10, 2026 · Grant37.0K
- Scheiner Zachary · June 10, 2026 · Grant37.0K
- Thedinga Angela · June 10, 2026 · Grant37.0K
- Ali Behbahani · June 10, 2026 · Grant37.0K
- Dybbs Michael · June 10, 2026 · Grant37.0K
- George Simeon · June 10, 2026 · Grant37.0K
- RA Capital Healthcare Fund LP · June 10, 2026 · Grant37.0K
- Leone D. Patterson · June 10, 2026 · Grant37.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 56.61M
- Total value held
- $115.93M
- Institutional holders
- 121
- Unknown10.81M
- Unknown4.51M
- Unknown3.57M
- Unknown3.51M
- Unknown3.33M
- Unknown3.15M
- Unknown2.52M
- Unknown2.08M
- Unknown2.05M
- Unknown2.01M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress
Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.